TIDMEDEN
RNS Number : 6419J
Eden Research plc
15 April 2020
15 April 2020
Eden Research Plc
("Eden" or "Company")
Appointment of Director of Regulatory Affairs
Eden Research plc (AIM: EDEN), the AIM-quoted company focused on
sustainable biopesticides for use in global crop protection, animal
health and consumer products industries, today announces the
appointment of Dr. Michael Carroll as Director of Regulatory
Affairs.
Mike is a leading figure in the field of crop protection
products development and registration. He brings international
experience to the team having worked in the UK, Germany, Belgium
and the USA, with over 30 years' experience gained in the
agrochemical industries. Mike served tenures of over 10 years at
both Dow AgroSciences and Monsanto Agricultural Group, holding the
various positions including Global Registration Manager and
European Registration Manager. At Monsanto and Dow AgroSciences,
Mike's responsibilities included the global launch of herbicides
and fungicides, experience which will be highly relevant as Eden
executes on plans to expand its product offering.
More recently, Mike served as Head of Research and Development
for Arysta EMEA, the largest region in Arysta LifeSciences. He was
responsible for early stage development and registration of new
formulations, the defence of existing active substances, chemical
and biosolutions, and ensuring REACH (Registration, Evaluation,
Authorisation and restriction of Chemicals) compliance in Europe.
For the past year, Michael has been working for TSG Consulting
(AIM:SAG) an AIM-quoted Science Group company that provides
regulatory and scientific support to chemical companies around the
world.
Mike holds BSc and PhD degrees in biochemistry from the UK
universities of Bath and London, respectively, and throughout his
career has shown interest in how local politics ultimately controls
the regulatory process. Mike is a frequent speaker and published
author, regularly participating in Informa Ag Chem and Generics
speciality conferences and British Crop Production Council
conferences. In 2019, he presented at both of these events on the
topic of "The EU General Food Law and Transparency".
CEO Sean Smith commented: "Mike is a key appointment that
further demonstrates our focus on building a high-calibre team
around the core functions within our business. He brings
significant capabilities to the Company in the critical areas of
product registration and regulatory compliance. Mike has a wealth
of international experience which has given him invaluable
expertise in product registration globally. Mike comes with a long
track record of driving successful regulatory outcomes in the crop
protection industry, a network of key industry influencers, and
experience in senior roles at industry leaders such as Dow
AgroSciences and Monsanto. We are pleased to welcome him to
Eden."
For further information contact:
Eden Research plc www.edenresearch.com
Sean Smith
Alex Abrey 01285 359 555
Cenkos Securities plc (Nominated advisor
and broker)
Giles Balleny / Cameron MacRitchie (corporate
finance)
Michael Johnson (sales) 020 7397 8900
Hawthorn Advisors (Financial PR)
Lorna Cobbett eden@hawthornadvisors.com
Jana Tsiligiannis
Notes:
Eden Research is an AIM quoted company that develops and
supplies breakthrough biopesticide products and natural
microencapsulation technologies to the global crop protection,
animal health and consumer products industries
Eden's Sustaine encapsulation technology harnesses the biocidal
efficacy of naturally occurring chemicals produced by plants
(terpenes) and can be used with both natural and synthetic
compounds to enhance their performance and ease-of-use.
Sustaine microcapsules are naturally derived, plastic-free,
biodegradable micro-spheres derived from yeast extract. They
produce stabilised aqueous suspensions which, are easy to mix and
apply, have phased release patterns, are safer for the environment
and the crops themselves.
The European Chemicals Agency (ECHA) has proposed an EU-wide
restriction on the placing on the market or use of
"intentionally-added" microplastic particles. The proposed
restriction includes the use of microplastics for agricultural and
horticultural purposes, including polymers utilized for
controlled-release fertilizers, encapsulated plant protection
products (PPPs), seed coatings, and biocides.
By 2025 in the EU, pesticides containing synthetic polymer
microplastics are likely to be banned and removed from the market.
The only acceptable alternative is the substitution with
biodegradable formulations. Reformulated products will need to be
evaluated and registered within the five-year transition
period.
Sustaine is one of the only viable, proven and immediately
registerable solutions to the microplastics problem in formulations
requiring encapsulation.
Historically, terpenes have had limited commercial use in the
agrochemical sector due to their volatility, phytotoxicity and poor
solubility. Sustaine provides a unique, environmentally friendly
solution to these problems and enables terpenes to be used as
effective, low-risk agrochemicals.
Eden is developing these technologies through innovative
research and a series of commercial production, marketing and
distribution partnerships.
The Company has a number of patents and a pipeline of products
at differing stages of development targeting specific areas of the
global agrochemicals industry. To date, the Company has invested in
the region of 14m in developing and protecting its intellectual
property and seeking regulatory approval for products that rely
upon the Company's technologies. Revenues earned by the Company
have been modest whilst the Company has concentrated on securing
patent protection for its intellectual property, gaining regulatory
approvals, identifying suitable industrial partners, and entering
into commercial agreements.
In May 2013, the three actives that comprise Eden's first
commercial product, Mevalone, were approved as new ingredients for
use in plant protection products by the European Commission ("EC").
This represented a major milestone in the commercialisation of
Eden's technology and is a significant accomplishment for any
company. To illustrate this point, one should note that in 2013,
Eden's approvals represented 3 of only 10 new active ingredients
approved by the EC.
Mevalone is a foliar fungicide which has been authorised for
sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France,
Cyprus, Albania, Portugal and Macedonia.
Cedroz is a nematicide which has been authorised for sale in Malta, Belgium and Mexico.
Eden was admitted to trading on AIM on 11 May 2012 and trades
under the symbol EDEN.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOASFAFMLESSEEL
(END) Dow Jones Newswires
April 15, 2020 02:00 ET (06:00 GMT)
Eden Research (AQSE:EDEN.GB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eden Research (AQSE:EDEN.GB)
Historical Stock Chart
From Jul 2023 to Jul 2024